Table 2.
TARGET | DRUG | FOR THE TREATMENT OF | CLINICAL PROGRESSION |
---|---|---|---|
CB1r/CB2r AGONISTS |
Dronabinol | Schizophrenia [83] | Phase IIa |
Fear extinction [156] | Phase II (completed) | ||
THC | PTSD [157] | Phase IV | |
Nabilone | PTSD (nightmares) [101] | Phase II | |
Sativex (THC & CBD) |
Cannabis dependence w/ anxiety [158] | Phase I | |
Multiple Sclerosis (cognitive function & mood) [159] |
Phase IV | ||
CB1r/CB2r ANTAGONISTS |
Cannabidiol (CBD) |
Schizophrenia (psychotic symptoms) [160] | Phase II (completed) |
GWP42003 (CBD) | Schizophrenia [84] | Phase II | |
CB1r ANTAGONIST |
AVE-1625 | Schizophrenia (cotreatment w/ anti- psychotics) [161] |
Phase II (terminated) |
FAAH INHIBITORS |
URB597 | Schizophrenia [162] | Phase I |
SSR411298 | Major Depressive Disorder [153] | Phase II |